(9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a ...

China's economic trajectory continues to be a subject of global scrutiny, especially as its internal policies and external negotiations evolve rapidly.